HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040

Reuters

Nov 10

HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040

HCW Biologics Inc. has announced updated preclinical data for its lead product candidate, HCW11-040, a second-generation, tetra-valent pembrolizumab-based immune checkpoint inhibitor. The data were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC2025), held from November 5 to 9, 2025. HCW11-040 is a multi-functional fusion protein constructed using the company's TRBC platform and includes IL-15 and IL-7 domains as well as a TGF-β trap. Preclinical results demonstrated that HCW11-040 has PD-1/PD-L1 blocking activity comparable to pembrolizumab and showed enhanced expansion and activation of memory T cells, as well as improved anti-tumor activity against pancreatic cancer and leukemia cells in organoid models, without inducing excessive inflammatory responses. The company indicated plans to advance further IND-enabling studies for HCW11-040.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582873134"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582873134\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582873134?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582873134","market":"nz","top_or_hot":-1,"title":"HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/HCWB\">HCW Biologics Inc.</a> has announced updated preclinical data for its lead product candidate, HCW11-040, a second-generation, tetra-valent pembrolizumab-based immune checkpoint inhibitor. The data were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC2025), held from November 5 to 9, 2025. HCW11-040 is a multi-functional fusion protein constructed using the company's TRBC platform and includes IL-15 and IL-7 domains as well as a TGF-β trap. Preclinical results demonstrated that HCW11-040 has PD-1/PD-L1 blocking activity comparable to pembrolizumab and showed enhanced expansion and activation of memory T cells, as well as improved anti-tumor activity against pancreatic cancer and leukemia cells in organoid models, without inducing excessive inflammatory responses. The company indicated plans to advance further IND-enabling studies for HCW11-040.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/HCWB\">HCW Biologics Inc.</a> has announced updated preclinical data for its lead product candidate, HCW11-040, a second-generation, tetra-valent pembrolizumab-based immune checkpoint inhibitor. The data were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC2025), held from November 5 to 9, 2025. HCW11-040 is a multi-functional fusion protein constructed using the company's TRBC platform and includes IL-15 and IL-7 domains as well as a TGF-β trap. Preclinical results demonstrated that HCW11-040 has PD-1/PD-L1 blocking activity comparable to pembrolizumab and showed enhanced expansion and activation of memory T cells, as well as improved anti-tumor activity against pancreatic cancer and leukemia cells in organoid models, without inducing excessive inflammatory responses. The company indicated plans to advance further IND-enabling studies for HCW11-040.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL79Kr1s:1","article_id":"2582873134","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582873134","pubTimestamp":1762776296,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HCW Biologics Inc. has announced updated preclinical data for its lead product candidate, HCW11-040, a second-generation, tetra-valent pembrolizumab-based immune checkpoint inhibitor. The data were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer , held from November 5 to 9, 2025. HCW11-040 is a multi-functional fusion protein constructed using the company's TRBC platform and includes IL-15 and IL-7 domains as well as a TGF-β trap. Preclinical results demonstrated that HCW11-040 has PD-1/PD-L1 blocking activity comparable to pembrolizumab and showed enhanced expansion and activation of memory T cells, as well as improved anti-tumor activity against pancreatic cancer and leukemia cells in organoid models, without inducing excessive inflammatory responses. The company indicated plans to advance further IND-enabling studies for HCW11-040.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT striv","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HCWB":"HCW Biologics Inc.","BK4539":"次新股"},"translate_title":"HCW Biologics公布下一代免疫检查点抑制剂HCW11-040有希望的临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCWB":0.9},"content_text":"HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040\n    \n\nHCW Biologics Inc. has announced updated preclinical data for its lead product candidate, HCW11-040, a second-generation, tetra-valent pembrolizumab-based immune checkpoint inhibitor. The data were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC2025), held from November 5 to 9, 2025. HCW11-040 is a multi-functional fusion protein constructed using the company's TRBC platform and includes IL-15 and IL-7 domains as well as a TGF-β trap. Preclinical results demonstrated that HCW11-040 has PD-1/PD-L1 blocking activity comparable to pembrolizumab and showed enhanced expansion and activation of memory T cells, as well as improved anti-tumor activity against pancreatic cancer and leukemia cells in organoid models, without inducing excessive inflammatory responses. The company indicated plans to advance further IND-enabling studies for HCW11-040.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}